Irminger-Finger should buy BARD1 tech back if so confident of lung test success.. Obviously things are very nasty behind scenes or why not come to some agreement of combining BARD1/SubB2M and negotiate a reasonable bonus structure for lung test success given the new company structure. Any successful test is a win win for both parties. No legal expert but how can a court force payment of a full bonus based on fantasy tests while the company now has myriad other tech to pursue. Court will surely have to prove company board went against shareholder best interests by not persuing lung tests.
From a shareholder perspective it is very frustrating we own both tech not realising any synergies while some disgruntled entities continue to dump.
Ann: Update on Legal Proceedings and BARD1 Autoantibody Program, page-57
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
63.0¢ |
Change
0.045(7.69%) |
Mkt cap ! $69.47M | |||
| Open | High | Low | Value | Volume |
| 58.5¢ | 63.5¢ | 58.5¢ | $149.7K | 242.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 858 | 63.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 64.0¢ | 15000 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |